FDA Set To Make Key Decision On Restasis Generics
Akorn, Mylan And Teva Are In The Running For ANDA Approvals
Despite the door being opened for generic competition to Restasis more than a year, no FDA approvals for ANDAs referencing the eye-disease drug have been forthcoming. However, that could change before the year is out.
